GCS1 Antikörper (AA 51-150) (AbBy Fluor® 350)
-
- Target Alle GCS1 (MOGS) Antikörper anzeigen
- GCS1 (MOGS) (Mannosyl-Oligosaccharide Glucosidase (MOGS))
-
Bindungsspezifität
- AA 51-150
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser GCS1 Antikörper ist konjugiert mit AbBy Fluor® 350
-
Applikation
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Homologie
- Human,Mouse,Rat,Dog
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human GCS1
- Isotyp
- IgG
- Top Product
- Discover our top product MOGS Primärantikörper
-
-
- Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- GCS1 (MOGS) (Mannosyl-Oligosaccharide Glucosidase (MOGS))
- Andere Bezeichnung
- GCS1 (MOGS Produkte)
- Synonyme
- Afu6g04210 antikoerper, AO090701000141 antikoerper, Mogs antikoerper, CDG2B antikoerper, CWH41 antikoerper, DER7 antikoerper, GCS1 antikoerper, 1810017N02Rik antikoerper, AI181835 antikoerper, Gcs1 antikoerper, gcs1 antikoerper, im:7160827 antikoerper, wu:fe50a12 antikoerper, wu:fk09a10 antikoerper, zgc:158312 antikoerper, mannosyl-oligosaccharide glucosidase antikoerper, mannosyl-oligosaccharide glucosidase GCS1 antikoerper, mannosyl-oligosaccharide glucosidase L homeolog antikoerper, mannosyl oligosaccharide glucosidase antikoerper, glucosidase 1 antikoerper, AFUA_6G04210 antikoerper, Tc00.1047053511015.10 antikoerper, Tc00.1047053511805.10 antikoerper, LOC5576381 antikoerper, AOR_1_260114 antikoerper, MGYG_00305 antikoerper, TERG_01248 antikoerper, mogs.L antikoerper, TTHERM_00636930 antikoerper, LOAG_03690 antikoerper, Gcs1 antikoerper, MOGS antikoerper, Mogs antikoerper, mogs antikoerper
- Hintergrund
-
Synonyms: EC 3.2.1.106, glucosidase I, Mannosyl oligosaccharide glucosidase, Mannosyl-oligosaccharide glucosidase, Mogs, MOGS_HUMAN, Processing A glucosidase I, Processing A-glucosidase I.
Background: Glycosylation of asparagine residues in Asn-X-Ser/Thr motifs in proteins commonly occur in the lumen of the endoplasmic reticulum (ER). Glucosidase I catalyzes the first step in the N-linked oligosaccharide processing pathway. It specifically removes the distal alpha 1,2-linked glucose residue from the Glc3-Man9-GlcNAc2 oligosaccharide precursor. Glucosidase I contains a short cytosolic tail, a single pass transmembrane domain and a large C-terminal catalytic domain located on the luminal side of the ER. Mutations in the gene encoding Glucosidase I result in the congenital disorder glycosylation (CDG-IIb), which is characterized by generalized hypotonia, dysmorphic features, hepatomegaly, hypoventilation, feeding problems, seizures and death. Two point mutations in the Glucosidase I gene have been identified and result in amino acid substitutions, namely Arg486Thr and Phe652Leu, that affect polypeptide folding and active site formation.
- Gen-ID
- 7841
- Pathways
- SARS-CoV-2 Protein Interaktom
-